Infectious Complications in Association with Cytoreductive Chemotherapy for Malignant Diseases

REFERENCES

• Andremont A, Lancar R, An Le N, Hattchouel JM, Baron S, Tavakoli T et al. Secular trends in mortality associated with bloodstream infec-tions in 4268 patients hospitalized in a cancer referral center between 1975 and 1989. Clin Microbiol Infect 1996;1:160–167.
   PubMedGoogle Scholar
• Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966:64:328–340.
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcome of bacteraemia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247 59.
   Google Scholar
• Hathorn JW, Lyke K. Empirical treatment of febrile neutropenia: evolution of current thera-peutic approaches. Clin Infect Dis 1997; 24:256–265.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guide-lines for the use of antimicrobial agents in neu-tropenic patients with cancer. Clin Infect Dis. 2002;34:730–51.
   Web of Science ®Google Scholar
• Viscoli, C., The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother, 1998;41 Suppl D:65–80.
   Google Scholar
• Steingrimsdottir H, Gruber A, Kahn M, Björkholm M. Late infections after blood pro-genitor cell transplantation in patients with multiple myeloma. Am J Med. 2001;110:329–30.
   Google Scholar
• Baglin TP, Gray JJ, Marcus RE, Wreghitt TG. Antibiotic resistant fever associated with herpes simplex virus infection in neutropenic patients with haematological malignancy. J Clin Pathol 1989; 42:1255–8.
   PubMed Web of Science ®Google Scholar
• Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous can-didiasis: From the laboratory to the bedside. Clin Infect Dis 1996;22(Suppl 2):S73–88.
   Google Scholar
• Chatzinikolaou I, Abi-Said D, Bodey GP, Rol-ston KV, Tarrand JJ, Samonis G. Recent ex-perience with Pseudomonas aeruginosa bacte-raemia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000;160:501–9.
   PubMed Web of Science ®Google Scholar
• Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80:13 20.
   Google Scholar
• Zinner SH. Changing epidemiology of infec-tions in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacte-ria. Clin Infect Dis 1999;29:490–4.
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neu-tropenia. Clin Infect Dis 2002;34:1524–9.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Jadeja J, Elting . Pseudomonas bac-teraemia. Retrospective analysis of 410 epi-sodes. Arch Intern Med 1985;145: 1621–9.
   Google Scholar
• Jones RN. Contemporary antimicrobial suscep-tibility patterns of bacterial pathogens com-monly associated with febrile patients with neutropenia. Clin Infect Dis 1999;29:495–502.
   Google Scholar
• Oppenheim BA. The changing pattern of infec-tion in neutropenic patients. J Antimicrob Chemother 1998;41:7–11.
   PubMed Web of Science ®Google Scholar
• Engels EA, Lau J, Barza M. Efficacy of qui-nolone prophylaxis in neutropenic cancer pa-tients: a meta-analysis. J Clin Oncol 1998;16:1179–87.
   Google Scholar
• Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospi-tals: a three-year analysis. Clin Infect Dis. 1999;29:239–44.
   PubMed Web of Science ®Google Scholar
• Ramphal R. Is monotherapy for febrile neutro-penia still a viable alternative? Clin Infect Dis 1999;29: 508 14.
   Google Scholar
• Del Favero A, Menichetti F, Martino P, Bu-caneve G, Micozzi A, Gentile G, et al.; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. A multicenter, double-blind, placebo-controlled trial compar-ing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutro-penia. Clin Infect Dis 2001;33:1295–301.
   Google Scholar
• Moore RD, Smith CR, Lietman PS. The asso-ciation of aminoglycoside plasma levels with mortality in patients with gram-negative bacte-raemia. J Infect Dis 1984;149:443–8
   Google Scholar
• Goulet V, Marchetti P. Listeriosis in 225 non-pregnant patients in 1992: clinical aspects and outcome in relation to predisposing conditions. Scand J Infect Dis 1996;28:367–74.
   PubMed Web of Science ®Google Scholar
• Lorber B Listeriosis. State of the art clinical article. Clin Infect Dis 1997;24:1–11.
   Google Scholar
• Lamy B, Roy P, Carret G, Flandrois JP, De-lignette-Muller ML. What is the relevance of obtaining multiple blood samples for culture? A comprehensive model to optimize the strat-egy for diagnosing bacteraemia. Clin Infect Dis 2002;35:842–50.
   Google Scholar
• Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE. Guidelines for the management of intravascular catheterre- lated infection. Clin Infect Dis 2001;32:1249–72.
   PubMed Web of Science ®Google Scholar
• Heussel CP, Kauczor HU, Heussel GE, Fischer B, Begrich M, Mildenberger P, Thelen M. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem cell transplant recipients: use of high resolution computed to-mography. J Clin Oncol 1999;17:796–805.
   Google Scholar
• De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime com-pared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic pa-tients with cancer: a multicenter randomized trial. Ann Intern Med 1994;120:834–44.
   Google Scholar
• Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infec-tion. J Antimicrob Chemother 1998:41:13–24
   PubMed Web of Science ®Google Scholar
• Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975;135:715–9.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Rex JH. All catheter-related can-didemia is not the same: assessment of the bal-ance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002;34:600–2.
   PubMed Web of Science ®Google Scholar
• Caillot D, Casasnovas 0, Bernard A, Couaillier JF, Durand C, Cuisenier B, et al. Improved management of invasive pulmonary aspergillo-sis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139–47.
   Google Scholar
• Maschmeyer G, Link H, Hiddemann W, Meyer P, Helmerking M, Eisenmann E, et al.. Pulmo-nary infiltrations in febrile patients with neu-tropenia. Risk factors and outcome under em-pirical antimicrobial therapy in a randomized multicenter study. Cancer 1994;73:2296–304.
   Google Scholar
• Denning DW. Invasive aspergillosis. Clin In-fect Dis 1998;26:781–805.
   PubMed Web of Science ®Google Scholar
• Man KA, Patterson T, Denning D. Aspergillo-sis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002;16:875–94.
   Google Scholar
• Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and Safety of Voriconazole in the Treatment of Acute In-vasive Aspergillosis. Clin Infect Dis 2002;34:563–571.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Ben-nett JE, Greene RE, Oestmann JW, et al.; Inva-sive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–15.
   Google Scholar
• Maertens J et al. Intersci Conf Antimicrob Agents Chemother 2000;40:371, Abstract 403).
   Google Scholar
• Zahar JR, Robin M, Azoulay E, Fieux F, Nitenberg G, Schlemmer B. Pneumocystis ca-rinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin Infect Dis 2002;35:929–34.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemopro-phylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316:1627 32.
   Google Scholar
• Swerdloff JN, Filler SG, Edwards Jr JE. Severe candidal infections in neutropenic patients. Clin Infect Dis 1993;17(Suppl 2):5457–67.
   Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Project Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86:668–72.
   Google Scholar
• Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in pa-tients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764–71
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al.; The National Insti-tute of Allergy and Infectious Diseases Myco-ses Study Group. Voriconazole compared with liposomal amphotericin B for empirical anti-fungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225–34.
   Google Scholar
• Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infec-tions among hematopoietic stem cell transplant recipients. Recommendations of CDC, the In-fectious Diseases Society of America, and the American Society of Blood and Transplanta-tion. MMWR Morb Mortal Wkly Rep 2000; 49(RR-10): 1125.
   Google Scholar
• Ljungman P. Prevention and treatment of viral infections in stem cell transplant recipients. Brit J Haematol 2002;118:44–57
   PubMed Web of Science ®Google Scholar
• Martino R, Ramila E, Munoz JM, Peyret M, Portos JM, Laborda R, Sierra J. Respiratory vi-rus infection in adults with hematologic malig-nancies: a prospective study. Clin Infect Dis 200336:1–8.
   Google Scholar
• Wood MJ. Viral infections in neutropenia - current problems and chemotherapeutic control. Antimicrob Agents Chemother 41, Suppl D:81–93.
   Google Scholar
• Ljungman P, Lewensohn-Fuchs I, Carlens S. Larsson K, Lönnqvist B et al. Results of differ-ent strategies for reducing cytomegalvirus-associated mortality in allogeneic stem cell transplantrecipients.Transplantation1998;66:1330–4.
   Google Scholar
• Hodinka RL. The clinical utility of viral quanti-tation using molecular methods. Clin Diagn Vi-rol 1998;10:25–47
   PubMedGoogle Scholar
• Boeckh M, Boivin G. Quantitation of cy-tomegalvirus: methodologic aspects and clini-cal applications. Clin Microbiol Rev 1998;11:533–54.
   PubMed Web of Science ®Google Scholar
• La-Rosa A, Champlin R, Mirza N, Gajewski J, Giralt S, Rolston K, et al., Adenovirus infec-tions in adult recipients of blood and marrow transplants. Clin Infect Dis, 2001;32::871–876.
   Google Scholar
• Howard D, Phillips-II G, Reece D, Munn R, Henslee-Downey J, Pittard M, et al., Adenovi-rus infections in hematopoietic stem cell trans-plant recipients. Clin Infect Dis. 1999;29:1494–501.
   PubMed Web of Science ®Google Scholar
• Legrand F, Berrebi D, Houhou N, Freymuth F, Faye A, Duval M, et al., Early diagnosis of adenovirus infection and treatment with cido-fovir after bone marrow transplantationin chil-dren. Bone Marrow Transplant, 2001;27:621–6
   Google Scholar
• Elting LS, Rubenstein EB, Rolston K, Cantor SB, Martin CG, Kurtin D, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for qual-ity and cost of care. J Clin Oncol 2000;18:3699–706.
   PubMed Web of Science ®Google Scholar
• Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA. A double-blind comparison of empirical oral and intrave-nous antibiotic therapy for low-risk febrile pa-tients with neutropenia during cancer chemo-therapy. N Engl J Med 1999; 341:305–11.
   Google Scholar
• Kern WV, Cometta A, De Bock R, Lan-genaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999;341:312–8.
   Google Scholar
• Rolston KVI. New trends in patient manage-ment: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999;29:515–21.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multina-tional association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038–51.
   PubMed Web of Science ®Google Scholar
• Hubel K, Dale DC, Engert A, Liles WC. Cur-rent status of granulocyte (neutrophil) transfu-sion therapy for infectious diseases. J Infect Dis 2001;183:321–8
   PubMed Web of Science ®Google Scholar
• Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo Pa et al.; American Society of Clinical Oncology. 2000 update of recom-mendations for the use of hematopoietic col-ony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 2000;18: 3558 85.
   Google Scholar
• Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs2002;62Suppl1:1–15
   Google Scholar